Daily fisetin supplement to support healthy aging
Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial
This will see if taking one 100 mg fisetin capsule daily for seven weeks lowers inflammation and supports overall health in people aged 50 and older.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Hvidovre University Hospital Academic / other |
| Locations | 1 site (Hvidovre) |
| Trial ID | NCT07195318 on ClinicalTrials.gov |
What this trial studies
This is a randomized, triple-blind, placebo-controlled two-arm trial enrolling about 120 relatively healthy middle-aged and older adults. Participants will be randomly assigned to receive either a 100 mg fisetin capsule or a matching placebo once daily for seven weeks. The study will monitor markers of inflammation, overall health measures, and safety outcomes during and after the intervention. Enrollment is limited to participants who can read Danish and attend visits at the study site in Hvidovre, Denmark.
Who should consider this trial
Good fit: Relatively healthy adults aged 50 or older who can read Danish and are willing to stop other anti-aging or anti-inflammatory supplements or medications are ideal candidates.
Not a fit: People with active cancer, unstable or uncontrolled major medical conditions, recent vaccination, or recent use of interacting or anti-aging medications or supplements are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, daily low-dose fisetin could lower chronic inflammation and contribute to healthier aging in middle-aged and older adults.
How similar studies have performed: Most evidence for fisetin's anti-aging effects comes from animal studies, and human data are currently very limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Middle-aged or older adult (≥50 years), * Able to cooperate cognitively, * Able to read and understand Danish, Exclusion Criteria: * Inability or unwillingness to take oral supplements, * Chronic or recent (within 30 days) use of other anti-aging supplements, * Chronic or recent (within 30 days) treatment with medications having anti-aging effects (e.g., metformin, rapamycin, semaglutide), * Chronic or recent (within 30 days) treatment with anti-inflammatory medications, * Chronic or recent (within 30 days) treatment with the medications that can interact negatively with fisetin, * Recent (within 14 days) vaccination, * Treatment with another investigational drug or other intervention within 1 year, * Active cancer or current cancer treatment, * Unstable or uncontrolled major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer, requiring regular monitoring at the hospital * Planned medical and surgical procedures during the study period, * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules, * Presence of any condition that the investigator believes would put the participant at risk or would preclude the participant from successfully completing all aspects of the study
Where this trial is running
Hvidovre
- Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre — Hvidovre, Denmark (Recruiting)
Study contacts
- Study coordinator: Juliette Tavenier
- Email: juliette.tavenier@regionh.dk
- Phone: +45 38620958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.